Radiopharm Theranostics has banked US$2 million (AU$3.1 million) from American medical giant Lantheus for the sale of two preclinical antibody assets that target and help to diagnose aggressive cancers. Lantheus, a leading US-based radiopharmaceutical-focused company, is also set to tip in a further US$ 5 million (AU$7.5 million) via a placement at 5c a share – a 42 per cent premium to today's price – with an option for another US$5 million investment within six months. The placement will be subject to a shareholder meeting next week. The stage A funding by Lantheus is part of an earlier $70 million fundraising done by Radiopharm in June at the same price to institutional fund managers and sophisticated investors. The stage B funding comes in the form of an option within the next six months at the election of the US financier. I am delighted with the confidence demonstrated by Lantheus in settling the transfer and development agreement and making this payment ahead of the shareholder meeting later this month.